|
|
|
|
|
|
Precise particle sizing is key to formulation success. Advanced analytics overcome DLS limitations, providing reliable data that reduces risk and supports long-term product stability.
|
|
|
|
|
Nanomedicine development requires specialized expertise across formulation, analytics, manufacturing, and regulatory strategy. Join Bastiaan Buddingh, Ardena’s Principal Scientist & BD Director Nanomedicines, for an Outsourced Pharma Capabilities Update exploring nanoparticle technologies, scale-up challenges, and GMP readiness, drawing on experience from 100+ nanomedicine programs.
|
|
|
|
|
Ardena has launched We Know Development™, a new podcast about the people, decisions, and expertise behind drug development. In the first episode, Mark van Eldijk discusses nanoparticle science, advanced drug development, and what it takes to translate complex technologies from the lab toward medicines that can reach patients.
|
|
|
|
NEW RESOURCES FOR DEVELOPMENT & MANUFACTURING
|
|
|
|
|
Agglomeration can compromise powder flow, homogeneity, downstream processing, and yield. In this whitepaper, Kim Geurts, Scientist PR&D and Manufacturing within Ardena’s Enabling Chemistry team, explores how in-house delumping at Ardena Oss improves control and efficiency while reducing external dependencies, including a GMP OEB-5 client program that achieved a 98% yield.
|
|
|
|
MEET ARDENA AT CPHI MILAN
|
|
|
|
|
|
From Molecules To Miles: Step Up To The Challenge
|
Visiting CPHI Milan? Take on Ardena’s step challenge. Participants will receive a step-tracking watch to record their daily activity, with the top walker recognized each day. The challenge also supports a charitable contribution, turning every step into part of a shared effort for a good cause.
|
|
|
